CRL vs GH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CRL · Charles River$337.52 ▲ 7.83%
GH · Guardant Health$150.87 ▼ 1.67%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CRL +99.8%
- GH +54.1%
Head to head
| Metric | CRL | GH |
|---|---|---|
| Price | $337.52 | $150.87 |
| Change today | ▲ 7.83% | ▼ 1.67% |
| Market cap | $16.17B | $20.41B |
| Return, 3 months | +21.8% | -9.8% |
| Return, year to date | +69.2% | +47.7% |
| Return, 1 year | +100.8% | +56.0% |
| P/E (TTM) | 366.9 | – |
| P/B | 5.0 | -74.0 |
| P/E percentile vs own 5y | 96th | 8th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -2.7% | +44.3% |
| Net profit growth (YoY) | -101.4% | -20.3% |
| Gross margin | 32.7% | 65.0% |
| Operating margin | 11.7% | -39.7% |
| Net margin | -6.0% | -38.3% |
| Return on equity | -7.7% | – |
| Analyst target vs. price | +4.5% | +35.3% |
| Analyst buy share | 93% | 100% |
| RSI (14) | 54 | 37 |
| 30-day volatility | 59.5% | 55.1% |
| Max drawdown, 1 year | -33.9% | -33.0% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GH is the largest of the group by market value.
- CRL has returned the most over the past year.
- GH is growing revenue fastest.
- CRL keeps the most profit per dollar of sales.
- GH has been the calmest stock over the last 30 days.